Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
GSK (GSK) Stock Moves -0.58%: What You Should Know
09:50pm, Thursday, 15'th Sep 2022 Zacks Investment Research
GSK (GSK) closed the most recent trading day at $31.02, moving -0.58% from the previous trading session.
GSK 'sell' rating removed as Zantac liabilities expected to be US$5bn
07:44am, Thursday, 15'th Sep 2022
GSK PLC (LSE:GSK, NYSE:GSK) has been upgraded by Credit Suisse on the assumption that its potential liability for Zantac lawsuits will be much smaller than the US$12bn that has been wiped from its mar
GSK (GSK) Stock Sinks As Market Gains: What You Should Know
10:00pm, Wednesday, 14'th Sep 2022 Zacks Investment Research
GSK (GSK) closed the most recent trading day at $31.20, moving -1.36% from the previous trading session.
Gilead (GILD) Up on Settling HIV Drug Suit With Generic Players
09:44pm, Tuesday, 13'th Sep 2022 Zacks Investment Research
Gilead (GILD) enters settlement agreements with a few generic manufacturers to resolve the litigation and patent challenges associated with HIV treatments, such as Descovy, Vemlidy and Odefsey.
Pharma Stock Roundup: FDA Nod to AZN's Imfinzi for New Cancer & Other Updates
05:20pm, Friday, 09'th Sep 2022 Zacks Investment Research
FDA approves AstraZeneca's (AZN) Imfinzi combination for advanced metastatic biliary tract cancer and grants Breakthrough Therapy Designation to Pfizer's (PFE) Group B Streptococcus (GBS) vaccine.
GSK (GSK) Gains But Lags Market: What You Should Know
09:50pm, Thursday, 08'th Sep 2022 Zacks Investment Research
In the latest trading session, GSK (GSK) closed at $31.51, marking a +0.06% move from the previous day.
SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma
04:54pm, Thursday, 08'th Sep 2022 Zacks Investment Research
Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.
Gilead (GILD) Breast Cancer Drug Trodelvy Improves Survival
03:53pm, Thursday, 08'th Sep 2022 Zacks Investment Research
Gilead (GILD) breast cancer drug Trodelvy demonstrates a statistically significant and clinically meaningful improvement of 3.2 months in overall survival compared to chemotherapy.
Is Most-Watched Stock GSK PLC Sponsored ADR (GSK) Worth Betting on Now?
01:00pm, Thursday, 08'th Sep 2022 Zacks Investment Research
Glaxo (GSK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is Most-Watched Stock GSK PLC Sponsored ADR (GSK) Worth Betting on Now?
10:32am, Thursday, 08'th Sep 2022
Glaxo (GSK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
GSK plc (GSK) Citi's 17th Annual BioPharma Conference Earnings Call Transcript
01:47am, Thursday, 08'th Sep 2022
GSK plc (NYSE:GSK ) Citi's 17th Annual BioPharma Conference September 7, 2022 1:50 PM ET Company Participants Roger Connor - President, Global Vaccines & Global Health Phil Dormitzer - Senior Vice Pre
GSK's NDA for Daprodustat to be Reviewed by an FDA Panel
03:40pm, Wednesday, 07'th Sep 2022 Zacks Investment Research
GSK's regulatory applications for daprodustat are based on data from the ASCEND phase III program, consisting of five studies.
Making Healthcare More Efficient Could Benefit Select ETFs
11:40am, Wednesday, 07'th Sep 2022
The U.S. doesn't have nationalized healthcare comparable to some other developed countries, and it is home to one of the most lumbering, inefficient healthcare systems. It would be to the benefit of h
GSK targets further cut by investment banks over potential Zantac legal risks
08:16am, Wednesday, 07'th Sep 2022
Two major investment banks cut their target prices for GSK PLC (LSE:GSK, NYSE:GSK) as analysts drilled down into the potential fallout from the Zantac litigation and saw the potential for total liabil
Gilead (GILD) Announces Positive New Data on Breast Cancer Drug
02:16pm, Tuesday, 06'th Sep 2022 Zacks Investment Research
Gilead (GILD) breast cancer drug Trodelvy shows efficacy across HER2-low and IHC0 status in pre-treated metastatic breast cancer patients.
